United States — Food and Drug Administration & GSK plc

United States — Food and Drug Administration: The United States — Food and Drug Administration is currently reviewing bepirovirsen for fast-track approval, and its decision in October will be crucial for the drug's market entry in the United States.

GSK plc: As a developer and funder of bepirovirsen, GSK plc stands to benefit significantly from the drug's potential approval and market success, enhancing its reputation and financial outlook in the pharmaceutical industry.

United States — Food and Drug Administration: The United States — Food and Drug Administration>>> is currently reviewing two of GSK plc>>>'s experimental lung cancer treatments for approval, which are key assets in the acquisition by GSK plc>>>.

GSK plc: GSK plc>>> is being acquired by GSK plc>>> for $10.6 billion, representing a 40% premium to its last closing price. This acquisition validates GSK plc>>>'s innovative work in developing targeted cancer therapies, particularly for lung cancer, and provides its shareholders with significant value.

United States — Food and Drug Administration: The United States — Food and Drug Administration was mentioned in GSK plc's alleged false statements regarding its independent conclusion on the causal association between ranitidine therapy and cancer.

GSK plc: GSK plc is facing a class action lawsuit for allegedly making false and misleading statements regarding the safety of its drug Zantac and its awareness of NDMA contamination. This event could lead to significant financial liabilities for GSK plc.

United States — Food and Drug Administration: The United States — Food and Drug Administration was directed by Donald Trump to issue new guidance on acetaminophen and approved leucovorin for autism treatment, facing scrutiny for its scientific basis.

GSK plc: GSK plc, as the manufacturer of Wellcovorin (a branded version of leucovorin), was asked by the United States — Food and Drug Administration to file a new application with data on cerebral folate deficiency.

United States — Food and Drug Administration: The United States — Food and Drug Administration approved NUZOLVENCE, one of Innoviva's products.

GSK plc: GSK plc is a partner of Innoviva, from whom Innoviva receives royalties on sales of respiratory assets.